CARGO Therapeutics, Inc. Common Stock Asset Resilience Ratio
CARGO Therapeutics, Inc. Common Stock asset resilience ratio. CARGO Therapeutics, Inc. Common Stock (CRGX) has an Asset Resilience Ratio of 56.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See CARGO Therapeutics, Inc. Common Stock (CRGX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of CARGO Therapeutics, Inc. Common Stock (2023–2024)
Asset resilience ratio of CARGO Therapeutics, Inc. Common Stock from 2023 to 2024. This chart shows how CARGO Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. Read CARGO Therapeutics, Inc. Common Stock total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down CARGO Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see CARGO Therapeutics, Inc. Common Stock asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $144.82 Million | 56.0% |
| Total Liquid Assets | $144.82 Million | 56.00% |
Asset Resilience Insights
- Very High Liquidity: CARGO Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 56.00% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CARGO Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare CARGO Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 38.51% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 11.40% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
CARGO Therapeutics, Inc. Common Stock Asset Resilience Ratio by Year (2023–2024)
CARGO Therapeutics, Inc. Common Stock asset resilience ratio by year from 2023 to 2024. The table below shows the annual Asset Resilience Ratio data for CARGO Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 66.49% | $275.32 Million | $414.05 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $453.04 Million | -- |
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution design… Read more